Psy29 Modeling the Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States

St, Wang; Huang, Huapin; Shi, Huaizhong; Dun,; Chen, K; Chang, Edward; Korves, Caroline; Dhawan, Ravinder; Cakana, Andrew; Velde, Helgi van de; Esseltine, DL; Garrison, LP

doi:10.1016/s1098-3015(10)73031-x

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, budget impact analyses and other modeling studies have projected the costs for various treatments for relapsed/refractory MM based on data from large-scale clinical trials [26 - 28] and also evaluated the cost-effectiveness of the new treatments in terms of quality-of-life years [29,30,33,[35][36][37]. Using budget impact modeling, Fullerton et al found that the total costs associated with treatment for relapsed/refractory MM were lowest with single-agent BOR compared with THALdexamethasone, LEN-dexamethasone, and BOR-liposomal doxorubicin [28].…”

Section: Discussionmentioning

confidence: 99%

“…However, only a limited number of studies have assessed the relative costs associated with these novel therapies and their cost-effectiveness compared with other therapeutic approaches [25][26][27][28][29][30][31][32][33][34][35][36][37]. In particular, very few studies have been conducted using real-world cost data and assessing the economic burden on patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data

et al. 2013

View full text Add to dashboard Cite

Background. Treatment of multiple myeloma has dramatically improved with the introduction of bortezomib (BOR), thalidomide (THAL), and lenalidomide (LEN). Studies assessing health care costs, particularly economic burden on patients, are limited. We conducted a claims-based, retrospective analysis of total health care costs as well as patient burden (patient out-of-pocket costs and number of ambulatory/hospital visits) associated with BOR/THAL/LEN treatment versus other therapies (OTHER). Conclusions. Adjusted analyses of real-world claims data show that total health care costs, as well as patient out-of-pocket costs, are higher with THAL/LEN treatment episodes than with BOR/OTHER therapies. Additionally, similar rates of ambulatory visits suggest that any perceived advantage in patient convenience of the orally administered drugs THAL/LEN is not supported by these data. The Oncologist 2013;18:37-45 Implications for Practice: In addition to efficacy and safety considerations, economic factors associated with novel treatments are important issues for payers and patients. Claims data provide real-world insight into health care costs associated with treatment for multiple myeloma. In this study, total health care costs and patient out-of-pocket costs were measured during one year post-initiation and analyzed per treatment episode. Adjusted for patient characteristics, comorbidities, and line of treatment, the costs of "other" therapies (i.e., other chemotherapy or radiotherapy) and bortezomib were similar, but the costs of thalidomide or lenalidomide treatment were significantly higher. Despite different routes of administration for bortezomib (intravenous), and thalidomide and lenalidomide (oral), the number of ambulatory visits (i.e., clinic/physician office and hospital outpatient visits) appeared similar across therapies with the only significant difference being between the rates for lenalidomide and "other" treatment. These data show differential real-world costs and patient burden associated with these treatments and may support decision-making with regard to multiple myeloma treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data

et al. 2013

View full text Add to dashboard Cite

show abstract

“…[72][73][74][75][76] Of these evaluations, three compared MPT with MP 72,74,75 and two compared VMP with MPT and MP. 73,76 All three studies showed additional benefits from MPT compared with MP at additional cost, with cost per QALY gained ranging from £17,002 to £17,847 72,74 in the UK and being AUS$20,998 in Australia. 75 The two economic evaluations assessing VMP, MPT and MP showed that additional benefits were provided by VMP compared with MPT and by VMP and MPT compared with MP.…”

Section: Discussionmentioning

confidence: 99%

“…75 The two economic evaluations assessing VMP, MPT and MP showed that additional benefits were provided by VMP compared with MPT and by VMP and MPT compared with MP. The studies showed ICERs ranging from CAN$48,294 73 to US$56,109 76 per QALY gained for VMP compared with MP and CAN$31,975 per QALY gained 73 and dominance 76 for VMP compared with MPT. All of the studies had the involvement of the manufacturer of the interventions.…”

Section: Discussionmentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Picot

Cooper²,

Bryant³

et al. 2011

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAThe clinical effectiveness and costeffectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clin...

show abstract

Psy29 Modeling the Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States

Cited by 2 publications

References 0 publications

Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data

Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Contact Info

Product

Resources

About